NasdaqCM - Delayed Quote • USD
Processa Pharmaceuticals, Inc. (PCSA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -1.18 | -0.9 | -5.41 | -3.94 |
| Low Estimate | -1.18 | -0.9 | -7 | -6 |
| High Estimate | -1.18 | -0.9 | -3.82 | -1.89 |
| Year Ago EPS | -7.2 | -3.6 | -8.48 | -5.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -6.4 | -5.6 | -2 | -1.6 |
| EPS Actual | -7.2 | -3.6 | -1.6 | -1.7 |
| Difference | -0.8 | 2 | 0.4 | -0.1 |
| Surprise % | -12.50% | 35.70% | 20.00% | -6.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.18 | -0.9 | -5.41 | -3.94 |
| 7 Days Ago | 0 | 0 | -7 | -6 |
| 30 Days Ago | 0 | 0 | -7 | -6 |
| 60 Days Ago | 0 | 0 | -7 | -6 |
| 90 Days Ago | 0 | 0 | -7 | -6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PCSA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 83.60% | -- | -- | 5.40% |
| Next Qtr. | 75.00% | -- | -- | 10.90% |
| Current Year | 36.20% | -- | -- | 4.50% |
| Next Year | 27.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | HC Wainwright & Co.: Buy | 4/25/2024 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 3/6/2024 |
Related Tickers
BDRX Biodexa Pharmaceuticals Plc
1.3000
+80.56%
MLEC Moolec Science SA
1.4500
+2.11%
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
PALI Palisade Bio, Inc.
6.05
-2.89%
ABVC ABVC BioPharma, Inc.
1.4200
-10.69%
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
CYCC Cyclacel Pharmaceuticals, Inc.
1.5100
-5.63%
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
JAGX Jaguar Health, Inc.
0.1800
+5.88%